We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMDA
101
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$2.39M 0.01%
610,626
– –
CYPH
102
Cypherpunk Technologies Inc
CYPH
$64.8M
$2.24M 0.01%
55,971
– –
SERA icon
103
Sera Prognostics
SERA
$82.6M
$2.24M 0.01%
+201,562
New +$2.09M
SNDX icon
104
Syndax Pharmaceuticals
SNDX
$1.73B
$2.12M 0.01%
+110,729
New +$1.85M
LOGC
105
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$2.07M 0.01%
451,478
– –
EVFM
106
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.99M 0.01%
179,807
– –
TCRR
107
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$1.5M 0.01%
176,461
– –
TARA icon
108
Protara Therapeutics
TARA
$216M
$1.38M 0.01%
199,671
– –
INZY
109
DELISTED
Inozyme Pharma
INZY
$1.24M 0.01%
106,999
– –
KZR
110
DELISTED
Kezar Life Sciences
KZR
$1.21M 0.01%
13,968
– –
PASG icon
111
Passage Bio
PASG
$14.6M
$1.17M 0.01%
5,858
– –
AFMD
112
DELISTED
Affimed
AFMD
$1.02M ﹤0.01%
16,461
– –
SRZNW icon
113
Surrozen Inc Warrant
SRZNW
$36.6K
$950K ﹤0.01%
+833,333
New +$1.15M
OYST
114
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$728K ﹤0.01%
61,424
– –
BLCM
115
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$727K ﹤0.01%
249,123
– –
MREO
116
Mereo BioPharma
MREO
$51.2M
$708K ﹤0.01%
292,692
-2,166,707
-88% -$5.74M
ADCT icon
117
ADC Therapeutics
ADCT
$140M
– –
-1,418,107
Closed -$34.5M
APLS
118
DELISTED
Apellis Pharmaceuticals
APLS
– –
-2,271,917
Closed -$144M
ASMB icon
119
Assembly Biosciences
ASMB
$489M
– –
-175,718
Closed -$8.18M
KRRO icon
120
Korro Bio
KRRO
$147M
– –
-1,111
Closed -$553K
PTGX icon
121
Protagonist Therapeutics
PTGX
$8.65B
– –
-455,276
Closed -$20.4M
SPRY icon
122
ARS Pharmaceuticals
SPRY
$574M
– –
-238,095
Closed -$7.36M
SYRS
123
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-6,550
Closed -$357K
ORTX
124
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-119,200
Closed -$5.23M
ISEE
125
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,406,037
Closed -$8.87M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Baker Bros. Advisors held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Baker Bros. Advisors's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Baker Bros. Advisors fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Baker Bros. Advisors opened 12 new positions and closed 10 in Q3 2021.
  • Baker Bros. Advisors's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.